4DMT reports pipeline progress; Fabry trial halted after aHUS, FDA aligns on endpoints

4D Molecular Therapeutics, Inc.

Filed IND for Phase 2 SPECTRA trial of 4D-150 in DME; enrollment expected Q3 2023.
Initiated randomized Phase 2 PRISM trial in wet AMD; 50 patients, 2:2:1 vs aflibercept.
Fabry program: 3 aHUS cases among 6 patients; one grade 4 DLT requiring hemodialysis.
Cardiac efficacy promising: improvements in peak VO2, KCCQ, GLS in evaluable patients.
FDA aligned on pivotal endpoints (peak VO2, KCCQ); co. halts enrollment, will re-evaluate in H2 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.